Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents-Reference-Cited by-同舟云学术

Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents

Published:2022-05-27 Issue:6 Volume:149 Page:
ISSN:0031-4005
Container-title:Pediatrics
language:en
Short-container-title:

Author:

Messiah Sarah E.¹²³,DeSantis Stacia M.⁴,Leon-Novelo Luis G.⁴,Talebi Yashar⁴,Brito Frances A.⁴,Kohl Harold W.⁵⁶,Valerio-Shewmaker Melissa A.⁷,Ross Jessica A.⁴,Swartz Michael D.⁴,Yaseen Ashraf⁴,Kelder Steven H.⁵,Zhang Shiming⁴,Omega-Njemnobi Onyinye S.⁵,Gonzalez Michael O.⁴,Wu Leqing⁴,Boerwinkle Eric⁴,Lakey David L.⁶,Shuford Jennifer A.⁸,Pont Stephen J.⁸

Affiliation:

1. aCenter for Pediatric Population Health

2. bThe University of Texas Health Science Center at Houston, School of Public Health in Dallas, Dallas,Texas

3. gChildren’s Health System of Texas, Dallas, Texas

4. cThe University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, Texas

5. dThe University of Texas Health Science Center at Houston, School of Public Health in Austin, Austin, Texas

6. fThe University of Texas System, Austin, Texas

7. eThe University of Texas Health Science Center at Houston, School of Public Health in Brownsville, Brownsville, Texas

8. hTexas Department of State Health Services, Austin, Texas

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology and Child Health

Link

https://publications.aap.org/pediatrics/article-pdf/doi/10.1542/peds.2021-055505/1296030/peds_2021055505.pdf

Reference8 articles.

1. American Academy of Pediatrics and the Children’s Hospital Association . Children and COVID-19: state data report. Available at: https://www.aap.org/en/pages/2019- novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data- report/. Accessed February 4, 2022

2. Estimated prevalence of SARS-CoV-2 antibodies in the Texas pediatric population. [published online ahead of print June 16, 2021];Messiah;Lancet

3. Strategies to estimate prevalence of SARS-CoV-2 antibodies in a Texas vulnerable population: results from phase I of the Texas Coronavirus Antibody REsponse Survey (TX CARES);Valerio-Shewmaker;Front Public Health

4. Estimation of total immunity to SARS-Cov-2 in Texas. [published online ahead of print August 7, 2021];DeSantis;medRxiv

5. Roche . Elecsys Anti-SARS-CoV-2. Package insert 2020-07, V9.0; material numbers 09203095190 and 09203079190. Available at: https://www.fda.gov/media/137605/download. Accessed May 3, 2022

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with elevated SARS-CoV-2 immune response in children and adolescents;Frontiers in Pediatrics;2024-08-15

2. The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: a cross sectional study;2024-03-04

3. RE: Incidence of SARS-CoV-2 Breakthrough Infections After Vaccination in Adults: A Population-Based Survey Through 1 March 2023;Open Forum Infectious Diseases;2023-11-29

4. Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents;Pediatric Research;2023-10-24

5. SARS-CoV-2 infections in a triad of primary school learners (grades 1-7), their parents and teachers in KwaZulu-Natal, South Africa: A pilot study protocol (Preprint);2023-09-13